JP5060284B2 - ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列 - Google Patents

ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列 Download PDF

Info

Publication number
JP5060284B2
JP5060284B2 JP2007505491A JP2007505491A JP5060284B2 JP 5060284 B2 JP5060284 B2 JP 5060284B2 JP 2007505491 A JP2007505491 A JP 2007505491A JP 2007505491 A JP2007505491 A JP 2007505491A JP 5060284 B2 JP5060284 B2 JP 5060284B2
Authority
JP
Japan
Prior art keywords
seq
protein
env
immunosuppressive
mutant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2007505491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008506357A (ja
JP2008506357A5 (enExample
Inventor
レナール，マルティアル
マンジェネイ，マリアンヌ
エイドマン，ティエリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Université Paris-Sud
Original Assignee
Centre National de la Recherche Scientifique
Institut Gustave Roussy
Université Paris-Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique, Institut Gustave Roussy, Université Paris-Sud filed Critical Centre National de la Recherche Scientifique
Publication of JP2008506357A publication Critical patent/JP2008506357A/ja
Publication of JP2008506357A5 publication Critical patent/JP2008506357A5/ja
Application granted granted Critical
Publication of JP5060284B2 publication Critical patent/JP5060284B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2007505491A 2004-03-30 2005-03-30 ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列 Expired - Fee Related JP5060284B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04290838 2004-03-30
EP04290838.4 2004-03-30
PCT/EP2005/003339 WO2005095442A1 (en) 2004-03-30 2005-03-30 Polypeptide sequence involved in the modulation of the immunosuppresive effect of viral proteins

Publications (3)

Publication Number Publication Date
JP2008506357A JP2008506357A (ja) 2008-03-06
JP2008506357A5 JP2008506357A5 (enExample) 2011-02-03
JP5060284B2 true JP5060284B2 (ja) 2012-10-31

Family

ID=34896141

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007505491A Expired - Fee Related JP5060284B2 (ja) 2004-03-30 2005-03-30 ウイルスタンパク質の免疫抑制作用のモデュレーションに関与するポリペプチド配列

Country Status (14)

Country Link
US (2) US8178657B2 (enExample)
EP (1) EP1732585B1 (enExample)
JP (1) JP5060284B2 (enExample)
CN (1) CN1961001B (enExample)
AT (1) ATE472334T1 (enExample)
AU (1) AU2005229411B2 (enExample)
BR (1) BRPI0509497B1 (enExample)
CA (1) CA2561376C (enExample)
DE (1) DE602005022056D1 (enExample)
ES (1) ES2347445T3 (enExample)
IL (1) IL178205A (enExample)
MX (1) MXPA06011272A (enExample)
WO (1) WO2005095442A1 (enExample)
ZA (1) ZA200608178B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9777044B2 (en) 2003-05-02 2017-10-03 Centre National De La Recherche Scientifique (Cnrs) GLUT-1 as a receptor for HTLV envelopes and its uses
EP2402447A1 (en) 2005-03-30 2012-01-04 Viroxis Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof
US20080299150A1 (en) * 2007-05-08 2008-12-04 Sankhia Corporation Method and system for processing immuno-competent cells in view of an antiviral therapy, and related therapeutic process
US8323891B2 (en) * 2008-08-01 2012-12-04 Claflin University miRNA triplex formations for the downregulation of viral replication
RU2008140688A (ru) * 2008-10-15 2010-04-20 Михаил Аркадьевич Шурдов (RU) Иммуносупрессивный пептид
WO2010079208A1 (en) 2009-01-09 2010-07-15 Centre National De La Recherche Scientifique New receptor binding ligands, their use in the detection of cells with biological interest
WO2011092199A1 (en) * 2010-01-26 2011-08-04 Institut Gustave Roussy Mutated xmrv env proteins in the immunosuppressive domain
US20130197612A1 (en) 2010-02-26 2013-08-01 Jack W. Lasersohn Electromagnetic Radiation Therapy
WO2012035369A1 (en) * 2010-09-17 2012-03-22 Centre National De La Recherche Scientifique Method for the diagnosis and/or prognosis of inflammatory states
RS58289B1 (sr) * 2011-07-20 2019-03-29 Merial Ltd Rekombinantna vakcina protiv virusa mačje leukemije koja sadrži optimizovani gen omotača virusa mačje leukemije
US9636396B2 (en) 2011-12-07 2017-05-02 Centre National De La Recherche Scientifique Mutant human and simian immunodeficiency virus ENV proteins with reduced immunosuppressive properties
EP2788372B1 (en) * 2011-12-07 2019-07-10 Viroxis S.A.S. Mutated lentiviral env proteins and their use as drugs
CA2912354C (en) 2013-06-07 2023-01-24 Viroxis S.A.S. Mutated non-primate lentiviral env proteins and their use as drugs
JP6864364B2 (ja) * 2015-06-11 2021-04-28 学校法人慶應義塾 融合タンパク質又は複合タンパク質、細胞内送達用担体、部分ペプチド、細胞膜透過促進剤、ｄｎａ、及びベクター
CA2999792A1 (en) * 2015-10-01 2017-04-06 Magdalena Janina LASKA Use of human derived immunosuppressive proteins and peptides as medicaments
US11351247B2 (en) 2017-09-01 2022-06-07 Inprother Aps Vaccine for use in the prophylaxis and/or treatment of a disease
US20210403907A1 (en) 2018-09-18 2021-12-30 Vnv Newco Inc. Arc-based capsids and uses thereof
EP3852813A4 (en) 2018-09-18 2022-06-22 VNV Newco Inc. ARC-BASED CAPSIDS AND THEIR USES
US11129892B1 (en) 2020-05-18 2021-09-28 Vnv Newco Inc. Vaccine compositions comprising endogenous Gag polypeptides
US20240093233A1 (en) 2021-01-13 2024-03-21 Viroxis Measles-hiv or measles-htlv vaccine
EP4392053A4 (en) * 2021-08-23 2025-06-25 Gabet, Yankel COMPOSITIONS AND METHODS FOR THE TREATMENT OF BONE DISEASES OR CONDITIONS
WO2024218400A1 (en) 2023-04-21 2024-10-24 Inprother Aps Improved expression of surface-displayed antigens
CN121717880A (zh) * 2025-12-25 2026-03-24 中国海洋大学青岛海上丝路研究院 许氏平鲉内源性逆转录病毒包膜蛋白percomORF、慢病毒载体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4822606A (en) 1986-04-07 1989-04-18 Duke University Immunosuppressive synthetic peptides and analogs thereof based on retroviral envelope sequences
EP0377842B1 (en) 1988-12-13 1995-10-04 President And Fellows Of Harvard College Prototype FeLV isolates for use in disease models and vaccines
FR2771011B1 (fr) * 1997-11-17 2000-01-28 Hippocampe Obtention de vaccins destines a prevenir les effets pathogenes associes a une infection retrovirale
FR2780069B1 (fr) * 1998-06-23 2002-06-28 Inst Nat Sante Rech Med Famille de sequences nucleiques et de sequences proteiques deduites presentant des motifs retroviraux endogenes humains et leurs applications
WO2001031021A1 (en) * 1999-10-28 2001-05-03 Universite De Geneve Multiple sclerosis-related superantigen
CA2429755A1 (en) * 2000-12-11 2002-06-20 Tufts University Treatment and prevention of ebv infection and ebv-associated disorders
GB0112126D0 (en) 2001-05-18 2001-07-11 Allergene Inc Composition

Also Published As

Publication number Publication date
US8178657B2 (en) 2012-05-15
JP2008506357A (ja) 2008-03-06
ES2347445T3 (es) 2010-10-29
ZA200608178B (en) 2008-10-29
EP1732585A1 (en) 2006-12-20
ATE472334T1 (de) 2010-07-15
AU2005229411A1 (en) 2005-10-13
BRPI0509497B1 (pt) 2022-07-19
IL178205A (en) 2015-05-31
US20120189647A1 (en) 2012-07-26
US20080008683A1 (en) 2008-01-10
BRPI0509497A (pt) 2007-09-11
WO2005095442A8 (en) 2006-11-02
WO2005095442A1 (en) 2005-10-13
AU2005229411B2 (en) 2010-11-18
US8597657B2 (en) 2013-12-03
MXPA06011272A (es) 2007-04-17
DE602005022056D1 (de) 2010-08-12
CN1961001A (zh) 2007-05-09
CN1961001B (zh) 2012-09-05
CA2561376A1 (en) 2005-10-13
IL178205A0 (en) 2006-12-31
EP1732585B1 (en) 2010-06-30
CA2561376C (en) 2016-06-21

Similar Documents

Publication Publication Date Title
US8597657B2 (en) Mutated env sequence involved in the modulation of the immunosuppressive effect of viral proteins
US10335482B2 (en) Method of inducing an anti-HIV-1 immune response comprising administering a C5/TM-GP41 peptide dimer
PT1035865E (pt) Tat do hiv-1 ou respectivos derivados para vacinação profiláctica e terapêutica
CA2675257A1 (en) Hiv combination vaccine and prime boost method
WO2022094287A1 (en) Multivalent particles compositions and methods of use
JP6612237B2 (ja) ヒトｔリンパ向性ウイルス１型に対する免疫応答を生成するためのレンチウイルスベクター
US20140227311A1 (en) Method for Removing Immunosuppressive Properties of HIV Envelope Glycoproteins
KR20230112691A (ko) 바이러스 감염을 치료하기 위한 방법 및 조성물
US20220184202A1 (en) A recombinant htlv-1 vaccine
RU2654673C2 (ru) Мутантные лентивирусные белки env и их применение в качестве лекарственных средств
Bongard et al. Interference of retroviral envelope with vaccine-induced CD8+ T cell responses is relieved by co-administration of cytokine-encoding vectors
WO2011092199A1 (en) Mutated xmrv env proteins in the immunosuppressive domain
US20060142219A1 (en) Pharmaceutical compositions comprising an hiv envelope protein and cd4
US10143737B2 (en) Method for the vaccination against HIV
US20250289867A1 (en) Multivalent particles compositions and methods of use
JP2002501369A (ja) Ｆｉｖワクチン
EP0763123A1 (en) Safe retroviral vectors, their production and use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080328

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101117

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20101117

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20101117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20101117

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20101119

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20101124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20111007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120105

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120410

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120628

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120710

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120731

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120803

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150810

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 5060284

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees